Nautilus Selling And Marketing Expenses vs Research Development Analysis

NAUT Stock

USD 2.01 0.03 1.47%

Nautilus Biotechnology financial indicator trend analysis is infinitely more than just investigating Nautilus Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nautilus Biotechnology is a good investment. Please check the relationship between Nautilus Biotechnology Selling And Marketing Expenses and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

Selling And Marketing Expenses vs Research Development

Selling And Marketing Expenses vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nautilus Biotechnology Selling And Marketing Expenses account and Research Development. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Nautilus Biotechnology's Selling And Marketing Expenses and Research Development is -0.45. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Research Development in the same time period over historical financial statements of Nautilus Biotechnology, assuming nothing else is changed. The correlation between historical values of Nautilus Biotechnology's Selling And Marketing Expenses and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Nautilus Biotechnology are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Selling And Marketing Expenses i.e., Nautilus Biotechnology's Selling And Marketing Expenses and Research Development go up and down completely randomly.

Correlation Coefficient

-0.45

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Selling And Marketing Expenses

Research Development

Most indicators from Nautilus Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nautilus Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.Selling General Administrative is likely to drop to about 25.5 M in 2025. Enterprise Value Over EBITDA is likely to drop to -4.94 in 2025

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	3.4M	5.0M	5.8M	3.8M
Cost Of Revenue	3.4M	5.7M	6.6M	3.9M

Reconciled Depreciation Cost Of Revenue

Nautilus Biotechnology fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Currrent Assets Other	Other Assets	Property Plant Equipment	Warrants
Total Assets		-0.26	0.7	0.76	0.95	-0.64	-0.76	0.72	0.23	-0.5	-0.27	0.81	-0.5	-0.38	0.5	0.87	-0.52	0.88	0.85	0.9	0.9	0.91	0.73	0.87	0.42	-0.3
Short Long Term Debt Total	-0.26		0.07	0.06	0.05	0.79	-0.09	-0.02	-0.62	-0.46	-0.11	0.04	-0.46	0.92	0.46	0.04	-0.65	0.04	0.08	0.05	0.02	0.02	-0.01	0.05	-0.05	-0.07
Other Current Liab	0.7	0.07		0.98	0.77	-0.15	-0.96	0.31	-0.13	-0.76	-0.01	0.95	-0.76	0.0	0.76	0.93	-0.69	0.75	0.94	0.9	0.88	0.89	0.85	0.93	0.69	-0.74
Total Current Liabilities	0.76	0.06	0.98		0.84	-0.23	-0.98	0.43	-0.11	-0.81	0.01	0.99	-0.81	0.01	0.81	0.97	-0.74	0.81	0.98	0.95	0.93	0.92	0.91	0.97	0.74	-0.69
Total Stockholder Equity	0.95	0.05	0.77	0.84		-0.41	-0.85	0.75	-0.01	-0.72	-0.23	0.88	-0.72	-0.07	0.72	0.93	-0.76	0.94	0.92	0.95	0.96	0.96	0.81	0.93	0.49	-0.33
Net Debt	-0.64	0.79	-0.15	-0.23	-0.41		0.18	-0.62	-0.31	-0.02	-0.12	-0.27	-0.02	0.72	0.02	-0.32	-0.19	-0.49	-0.29	-0.36	-0.35	-0.37	-0.41	-0.31	-0.27	-0.04
Retained Earnings	-0.76	-0.09	-0.96	-0.98	-0.85	0.18		-0.38	0.03	0.78	0.07	-0.98	0.78	0.0	-0.78	-0.95	0.75	-0.77	-0.96	-0.93	-0.94	-0.91	-0.87	-0.96	-0.69	0.6
Cash	0.72	-0.02	0.31	0.43	0.75	-0.62	-0.38		-0.28	-0.56	0.06	0.48	-0.56	0.0	0.56	0.57	-0.52	0.85	0.55	0.63	0.6	0.64	0.64	0.55	0.37	0.03
Non Current Assets Total	0.23	-0.62	-0.13	-0.11	-0.01	-0.31	0.03	-0.28		0.6	-0.57	-0.03	0.6	-0.81	-0.6	-0.02	0.48	-0.26	-0.07	-0.04	-0.02	-0.08	-0.31	-0.01	-0.39	0.06
Cash And Short Term Investments	-0.5	-0.46	-0.76	-0.81	-0.72	-0.02	0.78	-0.56	0.6		-0.29	-0.78	1.0	-0.52	-1.0	-0.76	0.91	-0.79	-0.79	-0.75	-0.78	-0.77	-0.88	-0.76	-0.79	0.4
Common Stock Total Equity	-0.27	-0.11	-0.01	0.01	-0.23	-0.12	0.07	0.06	-0.57	-0.29		-0.07	-0.29	0.29	0.29	-0.18	0.08	0.01	-0.14	-0.19	-0.09	-0.1	0.33	-0.17	0.66	0.09
Common Stock Shares Outstanding	0.81	0.04	0.95	0.99	0.88	-0.27	-0.98	0.48	-0.03	-0.78	-0.07		-0.78	-0.05	0.78	0.98	-0.74	0.82	0.99	0.97	0.95	0.92	0.89	0.99	0.69	-0.66
Short Term Investments	-0.5	-0.46	-0.76	-0.81	-0.72	-0.02	0.78	-0.56	0.6	1.0	-0.29	-0.78		-0.52	-1.0	-0.76	0.91	-0.79	-0.79	-0.75	-0.78	-0.77	-0.88	-0.76	-0.79	0.4
Non Current Liabilities Total	-0.38	0.92	0.0	0.01	-0.07	0.72	0.0	0.0	-0.81	-0.52	0.29	-0.05	-0.52		0.52	-0.08	-0.57	0.02	-0.03	-0.08	-0.05	-0.05	0.07	-0.07	0.18	0.05
Other Current Assets	0.5	0.46	0.76	0.81	0.72	0.02	-0.78	0.56	-0.6	-1.0	0.29	0.78	-1.0	0.52		0.76	-0.91	0.79	0.79	0.75	0.78	0.77	0.88	0.76	0.79	-0.4
Other Stockholder Equity	0.87	0.04	0.93	0.97	0.93	-0.32	-0.95	0.57	-0.02	-0.76	-0.18	0.98	-0.76	-0.08	0.76		-0.75	0.88	1.0	1.0	0.96	0.95	0.86	1.0	0.6	-0.62
Total Liab	-0.52	-0.65	-0.69	-0.74	-0.76	-0.19	0.75	-0.52	0.48	0.91	0.08	-0.74	0.91	-0.57	-0.91	-0.75		-0.74	-0.78	-0.76	-0.76	-0.75	-0.7	-0.76	-0.49	0.37
Total Current Assets	0.88	0.04	0.75	0.81	0.94	-0.49	-0.77	0.85	-0.26	-0.79	0.01	0.82	-0.79	0.02	0.79	0.88	-0.74		0.88	0.91	0.9	0.94	0.88	0.87	0.6	-0.32
Common Stock	0.85	0.08	0.94	0.98	0.92	-0.29	-0.96	0.55	-0.07	-0.79	-0.14	0.99	-0.79	-0.03	0.79	1.0	-0.78	0.88		0.99	0.96	0.95	0.88	1.0	0.63	-0.63
Net Tangible Assets	0.9	0.05	0.9	0.95	0.95	-0.36	-0.93	0.63	-0.04	-0.75	-0.19	0.97	-0.75	-0.08	0.75	1.0	-0.76	0.91	0.99		0.96	0.96	0.86	0.99	0.57	-0.58
Property Plant And Equipment Net	0.9	0.02	0.88	0.93	0.96	-0.35	-0.94	0.6	-0.02	-0.78	-0.09	0.95	-0.78	-0.05	0.78	0.96	-0.76	0.9	0.96	0.96		0.99	0.89	0.96	0.65	-0.43
Accounts Payable	0.91	0.02	0.89	0.92	0.96	-0.37	-0.91	0.64	-0.08	-0.77	-0.1	0.92	-0.77	-0.05	0.77	0.95	-0.75	0.94	0.95	0.96	0.99		0.88	0.95	0.62	-0.44
Non Currrent Assets Other	0.73	-0.01	0.85	0.91	0.81	-0.41	-0.87	0.64	-0.31	-0.88	0.33	0.89	-0.88	0.07	0.88	0.86	-0.7	0.88	0.88	0.86	0.89	0.88		0.86	0.9	-0.46
Other Assets	0.87	0.05	0.93	0.97	0.93	-0.31	-0.96	0.55	-0.01	-0.76	-0.17	0.99	-0.76	-0.07	0.76	1.0	-0.76	0.87	1.0	0.99	0.96	0.95	0.86		0.61	-0.62
Property Plant Equipment	0.42	-0.05	0.69	0.74	0.49	-0.27	-0.69	0.37	-0.39	-0.79	0.66	0.69	-0.79	0.18	0.79	0.6	-0.49	0.6	0.63	0.57	0.65	0.62	0.9	0.61		-0.39
Warrants	-0.3	-0.07	-0.74	-0.69	-0.33	-0.04	0.6	0.03	0.06	0.4	0.09	-0.66	0.4	0.05	-0.4	-0.62	0.37	-0.32	-0.63	-0.58	-0.43	-0.44	-0.46	-0.62	-0.39

Click cells to compare fundamentals

Nautilus Biotechnology Account Relationship Matchups

Nautilus Biotechnology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	85.0M	398.5M	350.1M	305.6M	351.4M	239.0M
Short Long Term Debt Total	4.8M	30.0M	30.3M	34.6M	31.2M	50.6M
Other Current Liab	1.1M	2.1M	1.5M	3.9M	4.5M	4.8M
Total Current Liabilities	3.0M	5.8M	6.8M	9.1M	10.5M	11.0M
Total Stockholder Equity	(29.7M)	363.6M	314.9M	265.4M	305.2M	171.8M
Net Debt	(31.8M)	(155.6M)	(84.2M)	15.2M	13.7M	14.4M
Retained Earnings	(30.3M)	(80.6M)	(138.6M)	(202.2M)	(182.0M)	(172.9M)
Cash	36.6M	185.6M	114.5M	19.4M	22.3M	21.2M
Non Current Assets Total	7.4M	49.2M	162.8M	128.7M	148.0M	90.6M
Cash And Short Term Investments	76.7M	345.7M	184.5M	173.4M	156.1M	148.3M
Common Stock Shares Outstanding	30.0M	84.5M	124.6M	124.9M	143.7M	150.8M
Short Term Investments	40.1M	160.1M	69.9M	154.0M	138.6M	131.7M
Liabilities And Stockholders Equity	85.0M	398.5M	350.1M	305.6M	351.4M	239.0M
Non Current Liabilities Total	111.7M	29.1M	28.3M	31.1M	28.0M	26.6M
Other Current Assets	303.8K	7.0M	2.7M	3.4M	3.9M	4.1M
Other Stockholder Equity	600K	444.4M	455.3M	467.8M	538.0M	564.9M
Total Liab	114.7M	34.9M	35.1M	40.2M	36.2M	48.8M
Total Current Assets	77.7M	349.2M	187.2M	176.8M	203.4M	148.4M
Property Plant And Equipment Net	6.2M	31.9M	32.6M	36.9M	42.4M	23.9M
Accounts Payable	470K	1.7M	1.3M	1.6M	1.9M	1.2M
Non Currrent Assets Other	527K	997K	1.1M	1.2M	1.4M	1.4M
Accumulated Other Comprehensive Income	3K	(184K)	(1.9M)	(255K)	(229.5K)	(241.0K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC